Abstract: The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

Abstract: The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

Abstract: The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

Abstract: Provided herein is an oral liquid suspension that includes topiramate, as well as methods of medical treatment that include orally administering the oral liquid suspension.

Abstract: An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg/mL for the treatment of attention-deficit/hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg/mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence.

Abstract: An oral liquid suspension comprising atomoxetine or a pharmaceutically acceptable salt thereof is disclosed, formulated at a concentration of about 20 mg/mL for the treatment of attention-deficit/hyperactivity disorder (ADHD). The suspension includes a dual preservative system (methylparaben and sodium benzoate), sweeteners, pH buffers, suspending agents, co-solvents, flavorants, and colorants. The composition demonstrates bioequivalence to Strattera® capsules, robust antimicrobial efficacy meeting USP <51> criteria, and physicochemical stability over 24 months in validated high-density polyethylene containers with child-resistant closures. The 20 mg/mL concentration enables precise dose titration for pediatric and dysphagic patients. Palatability is optimized through validated flavor masking studies, supporting high patient adherence.

Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a triptan or a pharmaceutically acceptable salt thereof, are described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease in a human patient, in particular migraine with or without aura, cluster headache, or trigeminal neuralgia, are also described.

Abstract: The present invention provides for a method of treating a person suffering from a psychiatric disorder that includes administration of a pharmaceutically effective amount of (i) nefazodone, or a pharmaceutically acceptable salt thereof, and (ii) risperidone. Also provided is a unit dose that includes (i) nefazodone, or a pharmaceutically acceptable salt thereof, (ii) risperidone, and (iii) one or more pharmaceutically acceptable excipients. Also provided is a therapeutic package that includes (a) the unit doses, (b) a finished pharmaceutical container that contains the unit doses, (c) printed indicia, and (d) optionally an outside container containing the finished pharmaceutical container and the printed indicia.

Abstract: A film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a triptan or a pharmaceutically acceptable salt thereof, are described. Methods for manufacturing such a film, and the use of such a film in the treatment of disease in a human patient, in particular migraine with or without aura, cluster headache, or trigeminal neuralgia, are also described.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a compound of Formula (I), such as adrenaline, or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of a condition selected from anaphylaxis, superficial bleeding and cardiac arrest.

Abstract: The present invention provides for a dosage form (e.g., liquid oral solution, liquid oral suspension, solid oral bead, granules, etc.) that contains one or more oncological active ingredients, methods of administering the same, and methods of manufacturing the same.

Abstract: The present invention provides for a method of treating a person suffering from a psychiatric disorder that includes administration of a pharmaceutically effective amount of (i) nefazodone, or a pharmaceutically acceptable salt thereof, and (ii) risperidone. Also provided is a unit dose that includes (i) nefazodone, or a pharmaceutically acceptable salt thereof, (ii) risperidone, and (iii) one or more pharmaceutically acceptable excipients. Also provided is a therapeutic package that includes (a) the unit doses, (b) a finished pharmaceutical container that contains the unit doses, (c) printed indicia, and (d) optionally an outside container containing the finished pharmaceutical container and the printed indicia.

Abstract: The present invention relates to an oral liquid suspension that includes lamotrigine and methods of medical treatment that include administering the oral liquid suspension. The oral liquid suspension has desirable physicochemical properties and technical attributes. The oral liquid suspension is useful in patients having difficulties in swallowing tablets and provide medical practitioners with additional options for dose titration.

Abstract: The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and a compound of Formula (I), such as adrenaline, or a pharmaceutically acceptable salt thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of a condition selected from anaphylaxis, superficial bleeding and cardiac arrest.

Abstract: The present invention provides for an oral solution containing trazodone, methods of manufacturing the same, and methods of using the same, e.g., to treat major depressive disorder (MDD).

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.

Abstract: According to an aspect of the disclosed embodiments, an apparatus for a vehicle includes a locking plate configured to be coupled to a first shaft of a suspension rod. A housing is configured to be coupled to a second shaft of the suspension rod that moves relative to the first shaft. The housing extends along a first longitudinal axis. A pin is configured to rotate about a second longitudinal axis. A locking mechanism is configured to lock the pin in starting position.

Abstract: The present invention provides for an oral liquid suspension that includes quetiapine or a pharmaceutically acceptable salt thereof. Also provided is a method for orally delivering quetiapine fumarate to a subject (e.g., for treating a mental disorder in a subject, such as schizophrenia, bipolar mania, and/or bipolar depression). The method includes orally administering to the subject an oral liquid suspension described herein.

Abstract: The present invention relates to a film comprising an alginate salt of a monovalent cation or a mixture of alginate salts containing at least one alginate salt of a monovalent cation, and an antagonist of an opioid receptor, an inverse agonist of an opioid receptor, or a prodrug thereof. The present invention further relates to methods for manufacturing such a film, and the use of such a film in the treatment of a human patient, in particular the use of such a film in the treatment of the effects of acute opioid overdose, or the use of such a film in reducing the risk of opioid abuse.